Get the Stockscreener App
0.8361
0.52%
0.0019
After Hours:
.83
-0.0061
-0.73%
Ocugen Inc stock is traded at $0.8361, with a volume of 2.90M.
It is up +0.52% in the last 24 hours and up +12.22% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.8342
Open:
$0.8342
24h Volume:
2.90M
Relative Volume:
0.72
Market Cap:
$244.17M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.0967
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-9.92%
1M Performance:
+12.22%
6M Performance:
-14.62%
1Y Performance:
-47.26%
1-Day Range:
$0.808
$0.8765
1-Week Range:
$0.808
$1.01
52-Week Range:
$0.515
$1.979
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.8361 | 266.89M | 0 | -63.08M | -72.53M | -0.27 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -
Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN
FDA grants Ocugen rare pediatric disease designation as voucher program remains in limbo - The Business Journals
Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST - marketscreener.com
Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therap - GuruFocus
FDA grants Ocugen’s OCU410ST rare pediatric disease status By Investing.com - Investing.com South Africa
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - Ocugen
Ocugen Announces Rare Pediatric Disease Designation Granted for - GuruFocus
FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com
FDA Grants Rare Pediatric Disease Designation to OCU410ST from Ocugen (OCGN) | OCGN Stock News - GuruFocus
Ocugen receives Rare Pediatric Disease Designation for OCU410ST - TipRanks
Ocugen Announces Rare Pediatric Disease Designation Granted - GlobeNewswire
FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood BlindnessNo Current Treatment Exists - Stock Titan
Northern Trust Corp Acquires 227,150 Shares of Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Tower Research Capital LLC TRC Has $32,000 Position in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Provides Business Update with First Quarter 2025 Financial Results - ADVFN
Noble Financial Predicts Ocugen’s Q2 Earnings (NASDAQ:OCGN) - Defense World
Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MSN
Ocugen stock price target cut to $7 by H.C. Wainwright - Investing.com Canada
Ocugen (NASDAQ:OCGN) Receives Buy Rating from Chardan Capital - Defense World
Ocugen (OCGN) Receives Ongoing "Buy" Rating from Chardan Capital - GuruFocus
Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus
Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga
Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track - MSN
Barclays PLC Decreases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Ocugen: Q1 Earnings Snapshot - New Haven Register
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo
Earnings call transcript: Ocugen’s Q1 2025 loss narrows, stock rises By Investing.com - Investing.com India
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
Earnings call transcript: Ocugen’s Q1 2025 loss narrows, stock rises - Investing.com
Ocugen’s Q1 2025: Progress in Gene Therapy Trials - TipRanks
Ocugen Inc’s Earnings Call: Optimism Amid Financial Challenges - TipRanks
Ocugen Provides Business Update with First Quarter 2025 Financia - GuruFocus
Ocugen Q1 2025 Earnings Call Transcript - MarketBeat
Ocugen (OCGN) Reveals Strong Q1 Revenue Growth and Strategic Cli - GuruFocus
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish By Stocktwits - Investing.com India
Ocugen (OCGN) Reveals Strong Q1 Revenue Growth and Strategic Clinical Advancements | OCGN Stock News - GuruFocus
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocugen Inc Stock (OCGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):